Biological Assembly 1  

 3D View: Structure | Electron Density

Global Symmetry: Cyclic - C3  (3D View)
Global Stoichiometry: Hetero 12-mer - A3B3C3D3 

Biological assembly 1 assigned by authors and generated by PISA (software)

Biological Assembly Evidence: gel filtration

Macromolecule Content

• Total Structure Weight: 99.61 kDa 
• Atom Count: 5684 
• Modelled Residue Count: 729 
• Deposited Residue Count: 898 
• Unique protein chains: 4

6BP2

Therapeutic human monoclonal antibody MR191 bound to a marburgvirus glycoprotein

• DOI: 10.2210/pdb6BP2/pdb

• Classification: VIRAL PROTEIN/immune system
• Organism(s): Marburg marburgvirus, Homo sapiens
• Expression System: Drosophila melanogaster, Nicotiana benthamiana
• Mutation(s): Yes 


• Deposited: 2017-11-21 Released: 2018-01-17 
• Deposition Author(s): King, L.B., Fusco, M.L., Flyak, A.I., Ilinykh, P.A., Huang, K., Gunn, B., Kirchdoerfer, R.N., Hastie, K.M., Sangha, A.K., Meiler, J., Alter, G., Bukreyev, A., Crowe, J.E.J., Saphire, E.O.
• Funding Organization(s): National Institutes of Health/National Institute Of Allergy and Infectious Diseases (NIH/NIAID)

---

Experimental Data Snapshot

• Method: X-RAY DIFFRACTION
• Resolution: 3.17 Å
• R-Value Free: 0.284 
• R-Value Work: 0.252 
• R-Value Observed: 0.254 

Literature

The Marburgvirus-Neutralizing Human Monoclonal Antibody MR191 Targets a Conserved Site to Block Virus Receptor Binding.

King, L.B., Fusco, M.L., Flyak, A.I., Ilinykh, P.A., Huang, K., Gunn, B., Kirchdoerfer, R.N., Hastie, K.M., Sangha, A.K., Meiler, J., Alter, G., Bukreyev, A., Crowe, J.E., Saphire, E.O.

(2018) Cell Host Microbe 23: 101-109.e4

• PubMed: 29324225 
• DOI: 10.1016/j.chom.2017.12.003
• Primary Citation of Related Structures:  
  6BP2


• PubMed Abstract: 
  

Since their first identification 50 years ago, marburgviruses have emerged several times, with 83%-90% lethality in the largest outbreaks. Although no vaccines or therapeutics are available for human use, the human antibody MR191 provides complete protection in non-human primates when delivered several days after inoculation of a lethal marburgvirus dose. The detailed neutralization mechanism of MR191 remains outstanding. Here we present a 3.2 Å crystal structure of MR191 complexed with a trimeric marburgvirus surface glycoprotein (GP). MR191 neutralizes by occupying the conserved receptor-binding site and competing with the host receptor Niemann-Pick C1. The structure illuminates previously disordered regions of GP including the stalk, fusion loop, CX ₆ CC switch, and an N-terminal region of GP2 that wraps about the outside of GP1 to anchor a marburgvirus-specific "wing" antibody epitope. Virus escape mutations mapped far outside the MR191 receptor-binding site footprint suggest a role for these other regions in the GP quaternary structure.

---

Organizational Affiliation: 

Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA; Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA 92037, USA. Electronic address: [e-mail].

Macromolecules

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details	Image
Envelope glycoprotein	A	250	Marburg marburgvirus	Mutation(s): 9  Gene Names: GP, DF49_53427gpGP
Find proteins for Q1PDC7 (Lake Victoria marburgvirus (strain Ravn-87)) Explore Q1PDC7  Go to UniProtKB:  Q1PDC7

Entity ID: 2
Molecule	Chains	Sequence Length	Organism	Details	Image
Envelope glycoprotein GP2	B	202	Marburg marburgvirus	Mutation(s): 4  Gene Names: GP, DF49_53427gpGP
Find proteins for Q1PDC7 (Lake Victoria marburgvirus (strain Ravn-87)) Explore Q1PDC7  Go to UniProtKB:  Q1PDC7

Entity ID: 3
Molecule	Chains	Sequence Length	Organism	Details	Image
MR191 Fab Heavy Chain	H	229	Homo sapiens	Mutation(s): 0

Entity ID: 4
Molecule	Chains	Sequence Length	Organism	Details	Image
MR191 Fab Light Chain	L	217	Homo sapiens	Mutation(s): 0

Oligosaccharides

Help

Entity ID: 5
Molecule	Chains	Chain Length	2D Diagram	Glycosylation
beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose	C	3		N-Glycosylation

Entity ID: 6
Molecule	Chains	Chain Length	2D Diagram	Glycosylation
2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose	D, F	2		N-Glycosylation

Entity ID: 7
Molecule	Chains	Chain Length	2D Diagram	Glycosylation
alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose	E	3		N/A

Experimental Data & Validation

Experimental Data

• Method: X-RAY DIFFRACTION
• Resolution: 3.17 Å
• R-Value Free: 0.284 
• R-Value Work: 0.252 
• R-Value Observed: 0.254 
• Space Group: P 3 2 1

Unit Cell:

Length ( Å )	Angle ( ˚ )
a = 133.796	α = 90
b = 133.796	β = 90
c = 151.003	γ = 120

Software Package:

Software Name	Purpose
PHENIX	refinement
XDS	data reduction
XDS	data scaling
PHENIX	phasing

Structure Validation

Entry History & Funding Information

Deposition Data

• Deposited Date: 2017-11-21 
• Released Date: 2018-01-17 
Deposition Author(s): King, L.B., Fusco, M.L., Flyak, A.I., Ilinykh, P.A., Huang, K., Gunn, B., Kirchdoerfer, R.N., Hastie, K.M., Sangha, A.K., Meiler, J., Alter, G., Bukreyev, A., Crowe, J.E.J., Saphire, E.O.

---

Funding Organization	Location	Grant Number
National Institutes of Health/National Institute Of Allergy and Infectious Diseases (NIH/NIAID)	United States	R01AI089498
National Institutes of Health/National Institute Of Allergy and Infectious Diseases (NIH/NIAID)	United States	U19AI109762

Revision History  

• Version 1.0: 2018-01-17
  Type: Initial release
  
• Version 1.1: 2018-01-31
  Changes: Database references
• Version 2.0: 2018-03-07
  Changes: Advisory, Atomic model, Derived calculations
• Version 2.1: 2019-12-11
  Changes: Author supporting evidence
• Version 3.0: 2020-07-29
  Type: Remediation
  Reason: Carbohydrate remediation
  Changes: Advisory, Atomic model, Data collection, Derived calculations, Structure summary